Braunold continued: "We see substantial opportunities to expand in the drugstore channel and beyond as we grow our product portfolio during 2013, particularly as our partner HoMedics looks to increase distribution worldwide via its extensive network in over 60 countries. We look forward to an exciting year ahead for the Company as our products enter the vast consumer wellness market, which in turn contributes to potentially increasing value for the SPO shareholders."
SPO is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: medical care; sports and wellness; homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spoglobal.com.
Forward Looking StatementsThis press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, expectations as to the realization of additional revenues from the order backlog, expectations as to increasing the order backlog in 2013, the success of efforts to expand distribution of our products, the success, if any, of our efforts to expand distribution of products to additional mass market retailers, the ability to create strategic partnerships to aid in the distribution of products, profitability, market acceptance of our products and new product applications, timing of new product launches, success of the Company's rebranding program, product performance, size of prospective markets, revenue assessments, marketing strategies, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. We undertake no obligation to revise or update any forward-looking statement for any reason. Contact regarding this release: SPO firstname.lastname@example.org +1-866-991-7766 SOURCE SPO Medical Inc.